Loading…

SterisSTECompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Provider of infection-prevention/sterilization products and services for hospitals and medtech manufacturers.

Momentum leader 86
Mkt cap
$25.2B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$214M
20-day average traded
Fwd P/E
21.9×
forward earnings
ROIC−WACC
+2.0 pp
WACC 9.1%
Hurdle
+0 pp
Req g minus delivered
Official | Implied
BBB / A-
agencies · bond market
Next earnings
84 days
10 Feb 2027
Close · USD$259.57
1D+0.8%
1W+1.3%
1M+15.3%
3M+10.1%
6M+20.6%
YTD+3.0%
1Y+1.6%
ATR %2.5%
Beta0.43
52w lowhigh3.1% off high

What Steris does

Provider of infection-prevention/sterilization products and services for hospitals and medtech manufacturers.

Earns a mix of one-off equipment sales to hospitals, recurring consumables and service contracts on installed equipment, and per-load fees where device makers pay to have products sterilised in its plants. The contract-sterilisation arm came with the 2015 purchase of Synergy Health. It is incorporated in Ireland but run from Ohio.

Products and services

  • Healthcare (sterilizers, surgical equipment)
  • Applied Sterilization Technologies (contract sterilization)
  • Life Sciences (pharma sterilization/decontamination)

Customers

  • Hospitals/surgery centers
  • Medical device manufacturers
  • Pharma/biopharma manufacturers

Where it sits in the supply chain

  • Healthcare
  • Infection prevention & sterilization
  • Sterilization equipment, consumables…

What could go right

  • Medical-device outsourced-sterilization demand growth
  • Hospital capital-equipment replacement

What could go wrong

  • Ethylene oxide regulatory/environmental scrutiny
  • Hospital capex cycle sensitivity

Moat: narrow (regulatory licence, switching costs, installed base). Outsourced sterilization requires regulatory-validated facilities that are costly and slow to replicate.

Headquarters: Dublin, Ireland (US operations Mentor, Ohio) · Founded: 1985 · Employees: 17,937

Named competitors

Steris at a glance

Size Steris (STE) is a United States Health Care company (Medical Specialties) with a market value of $25.2B, the 425th largest of 3,085 United States companies the cockpit tracks. Shares closed at $259.57 on 18 Nov 2026.

Performance Over six months the shares gained 20.6%, against +28.2% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 8.1% over the last twelve months (peer median +6.7%); the operating margin is 20.0% (peer median 18.2%).

Valuation It trades at 21.9× forward earnings against a peer median of 28.0× (6th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.0 points above its cost of capital (9.1% WACC).

Backlog Backlog (remaining performance obligations) was $1.53B at 30 Sep 2026, down 20% on a year earlier — 0.2 years of trailing revenue. Backlog detail →

Credit Steris has 2 bonds outstanding ($1.35B), rated BBB by the agencies and trading like A- at a weighted spread of 86 bp.

Short interest Short interest is 2.2% of the free float (30 Oct 2026).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 124STE 119
Six months, rebased to 100: Steris against the median of its 20 peers (local-currency closes).

Steris financials

Reported figures in USD; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$6.17B$5.94B$5.46B$5.14B$4.54B
Revenue growth—+9%+6%+13%—
Gross profit$2.79B$2.66B$2.42B$2.24B$1.98B
EBITDA$1.73B$1.63B$1.46B$1.47B$1.36B
Net income$827M$782M$629M$378M$107M
Free cash flow$937M$972M$776M$613M$395M
Capital expenditure$352M$369M$370M$360M$362M
Total debt$2.05B$2.09B$2.20B$3.38B$3.25B

Quarterly statements and history in the cockpit →

Steris competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

+20%+40%+60%-10%0%+10%+20%DIM4543WSTDXCMSTMNILMNSRTSOONGHZBH300760RMDMTDALCRVTYGEHCCOLO-B688271GKOSSTE6-month return →1-month return →
Up and to the right = strong over both horizons. Steris is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%0×50×100×150×DIM4543DXCMSTMNILMNSOONZBHRMD688271WATGKOSSTERevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Steris is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%DIM4543WSTDXCMSTMNILMNSOONZBH300760RMDMTDALCRVTYGEHCCOLO-BWATSTEGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Steris is the large dot.

Steris competitors and peer comparison

Head to head with its named competitors (STE vs SHC vs GETI-B.ST vs ECL)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Steris STE$25.2B+21%+8%20%21.9×14.0%
Sotera Health SHC$4.65B+5%+7%37%15.7×14.4%
Getinge GETI-B.ST$7.45B+40%-4%14%21.1×5.0%
Ecolab ECL$84.3B+21%+9%18%33.6×20.3%
Stryker SYK$121B-1%+8%25%19.9×10.7%
Fortive FTV$19.9B+13%-22%20%20.4×18.0%

How Steris compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Steris against its 20 peers (data as of 18 Nov 2026)
MeasureSTEPeer medianRank in peer set
1-month return+15.3%+5.7%3rd highest of 21
6-month return+20.6%+28.2%7th lowest of 21
Distance from 52-week high-3.1%-8.4%4th highest of 21
Revenue growth (TTM)+8.1%+6.7%9th highest of 21
Operating margin20.0%18.2%10th highest of 21
Forward P/E21.9×28.0×6th cheapest of 20
Growth the price implies (Req g, 7 yrs)14.0%16.2%9th least demanding of 18
Growth delivered (Del g)+13.8%+7.4%2nd highest of 18
Hurdle (Req g minus delivered)+0.2 pp+4.2 pp6th least demanding of 18
ROIC minus cost of capital+2.0 pp+3.2 pp10th lowest of 21
EV / EBITDA15.5×20.8×6th cheapest of 17
Net debt / EBITDA0.9×1.5×7th least indebted of 17
Bond spread86 bp90 bp4th tightest of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Steris STEUnited States$25.2B+21%+8%20%21.9×14.0%+13.8%
Sartorius Stedim Biotech DIM.PAFrance$24.2B+32%+4%19%45.7×33.4%+9.2%
Terumo 4543.TJapan$24.0B+32%+15%17%27.8×8.8%+13.0%
West Pharmaceutical Services WSTUnited States$28.1B+32%+13%23%40.2×25.8%+7.4%
Dexcom DXCMUnited States$30.8B+16%+13%24%28.0×19.6%+19.3%
Straumann STMN.SWSwitzerland$20.4B+20%+2%21%32.9×16.2%+12.8%
Illumina ILMNUnited States$31.8B+48%+6%21%35.2×27.2%+6.0%
Sartorius SRT.DEGermany$19.9B+26%+4%18%43.0×25.6%+8.7%
Sonova SOON.SWSwitzerland$19.8B+40%-6%23%25.3×6.0%+6.7%
Guardant Health GHUnited States$19.6B+26%+42%-39%n/an/an/a
Zimmer Biomet ZBHUnited States$19.6B+21%+7%16%11.7×7.4%+3.2%
Shenzhen Mindray Bio-Medical Electronics 300760.SZChina$33.6B+15%+5%28%27.3×1.0%+9.7%
ResMed RMDUnited States$34.1B+16%+9%34%19.7×5.7%+12.1%
Mettler Toledo MTDUnited States$34.6B+60%+7%29%33.7×20.1%+5.5%
Alcon ALC.SWSwitzerland$36.9B+18%+1%12%21.5×12.2%+6.1%
Revvity RVTYUnited States$17.0B+61%+5%16%26.2×26.4%-5.5%
GE HealthCare GEHCUnited States$37.8B+30%+7%14%15.6×5.0%+3.7%
Coloplast A/S COLO-B.CODenmark$16.6B+24%+4%25%20.0×-2.1%+8.3%
Shanghai United Imaging Healthcare 688271.SSChina$14.4B+4%+27%9%45.7×n/an/a
Waters WATUnited States$45.8B+37%+81%10%29.1×48.1%+6.0%
Glaukos GKOSUnited States$13.8B+62%+47%-9%161.5×n/an/a

Steris bonds and credit

Steris has 2 bonds outstanding with $1.35B face value. The agencies rate it BBB; its bonds trade like A-. Weighted yield 5.95%, a spread of 86 bp over government bonds.

Every bond, yield and spread in the cockpit →

Steris backlog

Steris reported $1.53B of remaining performance obligations at 30 Sep 2026, down 20% from a year earlier and down 0% from the previous quarter. That is 0.2 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.

Questions

Who are Steris's main competitors?
Named competitors: Sotera Health (SHC), Getinge AB (GETI-B.ST), Ecolab (ECL), Stryker (SYK), Fortive (FTV). The cockpit's measured peer set (industry) also includes Sartorius Stedim Biotech (DIM.PA), Terumo (4543.T), West Pharmaceutical Services (WST), Dexcom (DXCM), Straumann (STMN.SW), Illumina (ILMN).
Is Steris expensive compared with its peers?
On forward p/e it trades at 21.9× against a peer median of 28.0×, 6th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Steris stock performed?
Over six months to 18 Nov 2026 the shares returned +20.6% against +28.2% for the median peer; over one year +1.6%.
What is Steris's backlog?
Steris's remaining performance obligations (contracted revenue not yet recognised) were $1.53B at 30 Sep 2026, -20% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.